-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – FB-825 in Allergic Rhinitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FB-825 in Allergic Rhinitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FB-825 in Allergic Rhinitis Drug Details: FB-825 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pelcitoclax in Sezary Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pelcitoclax in Sezary Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Pelcitoclax in Sezary Syndrome Drug Details:Pelcitoclax (APG-1252) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vudalimab in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vudalimab in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vudalimab in Ovarian Cancer Drug Details: XmAb-717 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vudalimab in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vudalimab in Fallopian Tube Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vudalimab in Fallopian Tube Cancer Drug Details: XmAb-717 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Budigalimab in Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Budigalimab in Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Budigalimab in Head And Neck Cancer Squamous Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ranibizumab Biosimilar in Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ranibizumab Biosimilar in Macular Edema report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ranibizumab Biosimilar in Macular Edema Drug Details: Ranibizumab biosimilar (CHS-3351)...
-
Company Insights
Innovation and Patenting activity of Atreca Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Atreca Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Company Profile
Atreca Inc – Company Profile
Atreca Inc (Atreca) is a biotechnology company. It develops novel therapies based on the human immune response. The company develops proprietary immune repertoire capture technology that act as an engine for the discovery and development of antibody-based therapeutics, diagnostics, vaccines and research reagents. Its technology has partnerships with pharmaceutical companies, academic institutions, non-profit foundations and governmental entities. Its pipeline products are intended for the treatment of breast tumor, lung tumors, colon tumors and other solid tumors. Atreca is headquartered in...
Add to Basket -
Product Insights
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in the later stages of the disease. The signs and symptoms include a persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody...
-
Product Insights
Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colorectal Cancer Pipeline Drugs Market Overview Colorectal cancer starts in the colon or the rectum. It begins as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools, and weight loss with no known reasons. Risk factors for colorectal cancer include smoking, heavy alcohol use, inflammatory bowel disease (IBD), and family history. Treatment includes...